Family Med Journals

Family Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Perez OA et al. – Current therapies are primarily directed against the formation of these antibodies by suppression of the immune system, and are associated with significant adverse events. As our understanding of the pathophysiology of pemphigus increases, newer therapies have been proposed and evaluated. These novel therapies include intravenous immunoglobulin, plasmapheresis, immunoadsorption, extracorporeal photochemotherapy, biological agents, as well as experimental therapies such as cholinergic receptor agonists, Dsg3 peptides and a p38 mitogen–activated protein kinase inhibitor. Current limitations to the widespread use of these therapies include cost, a lack of consistent data regarding their benefit, limited availability, and the experimental nature of some of the treatments. This review highlights the latest case reports and studies that employ established as well as new therapeutics in a novel way to treat this rare, but serious, disorder.


   

Today in Clinical Pharmacology...keeping you current

New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09

Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09

Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09

Today in Dermatology...keeping you current

Skin fusion on the fingers and toes of an adolescent girl
The Clinical Advisor, 09/10/09

Erysipeloid: a review
Clinical and Experimental Dermatology, 09/18/09

Oral Allergy Syndrome
Allergology International, 10/30/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address